Navigation Links
Increased risk of relapse omitting RT in early PET scan negative Hodgkin lymphoma
Date:3/19/2014

Interim analysis of the intergroup EORTC-LYSA-FIL 20051 H10 trial published in the Journal of Clinical Oncology indicates an increased risk of early relapse when omitting radiotherapy in early PET scan negative patients with stage I/II Hodgkin's lymphoma. Early outcome, however, was excellent in both arms, and the final analysis should reveal whether these initial findings are maintained over time.

Dr. J.M.M. Raemaekers of the Radboud university medical center Nijmegen, The Netherlands, and central coordinator of the study says, "The standard treatment for patients with clinical stage I/II Hodgkin's Lymphoma is ABVD (adriamycin, bleomycin, vinblastin and dacarbazin) chemotherapy followed by radiotherapy. Striking the right balance between initial cure through combined modality treatment and accepting a higher risk of late complications, and a higher recurrence rate after omitting radiotherapy in subsets of patients who will subsequently need intensive salvage treatment, is a matter of unsettled debate."

The main objective of the H10 trial was to evaluate whether involved-node radiotherapy could be omitted without loss of efficacy in terms of progression-free survival in patients with stage I/II Hodgkin's Lymphoma who had a negative earlyPET scan after two cycles of ABVD chemotherapy. This interim trial analysis included a total of 1137 patients with untreated clinical stage I/II Hodgkin's Lymphoma. Of these, 444 patients had favorable and 693 unfavorable prognoses. Patients in each prognostic group were randomized between standard and experimental treatment and first received two cycles of ABVD chemotherapy. Patients in the experimental arm who attained a negative earlyPET scan after the two cycles of ABVD chemotherapy were spared involved-node radiotherapy.

For patients with a favorable prognosis and a negative earlyPET scan, one progression occurred in the standard arm and nine progressions occurred in the experimental arm. For patients with unfavorable prognosis and a negative earlyPET scan, seven events occurred in the standard arm and 16 events occurred in the experimental arm. Even though there were few events and the median follow-up time short, the Independent Data Monitoring Committee concluded it was unlikely that the final results would show non-inferiority for the experimental treatment. They, therefore, advised that randomization should be stopped for earlyPET negative patients.


'/>"/>

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. Gestational diabetes linked to increased risk for heart disease in midlife
2. Despite recession, childrens health spending increased between 2009-2012, says new report
3. Death of partner associated with increased risk of heart attack, stroke
4. Smoking linked with increased risk of most common type of breast cancer
5. New clues may link hereditary cancer genes to increased risk of cancer from alcohol
6. Patients with multiple sclerosis in Taiwan may be at increased risk of developing cancer
7. Increased risk of prostate cancer in African-American men; implications for PSA screening
8. No brakes -- Study finds mechanism for increased activity of oncogene in certain cancers
9. Hospital-diagnosed maternal infections linked to increased autism risk
10. Local Campaign to Educate African American Women on Increased Risk of Breast Cancer
11. In Light of Increased Levels of Personal Stress Over the Holiday Season, Lanahan Insurance Recommends Staying Covered with Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... ... Many people make New Year’s resolutions or renew their commitment to better health with the ... people who want to kick off 2017 with better smiles. Dr. Mondavi is offering several ... offers include: , , A new patient package for just $49, ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide comfort and fuel ... the fast-casual category, announces a hearty and wholesome Winter Menu. Starting today, guests ... Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky Chicken & Sausage ...
(Date:1/16/2017)... ... 16, 2017 , ... Gym Source, America’s leading retailer of premium residential and ... New Jersey. , “We are elated to be opening this new showroom,” explains Tom ... to give clients a seamless and motivating shopping experience.” , Every fitness journey is ...
(Date:1/16/2017)... ... ... Anybody who may be looking for a substance abuse rehabilitation program with a ... holistic treatment center for addiction located in Marne, MI. This video, which can be ... staff that visited the 2016 Recovery Palooza support event in nearby Grand Rapids. , ...
(Date:1/16/2017)... ... 2017 , ... Permobil has just completed the acquisition of ... systems has a well-earned reputation for premium quality, with a focus on fit ... in the custom seating business, which enjoys strong demand, and it complements Permobil’s ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017  From the company that brought a full line of ... comes a new line of companion animal pet first aid kits.  ... equine first aid, has developed two sizes of small pet first ... Inc. Featuring a small and a large companion pet ... family, is not a newcomer to working with small animals either. ...
(Date:1/17/2017)... YORK , Jan. 17, 2016  Attorney Advertising -- ... behalf of purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the ... to obtain additional information and assist the investigation by visiting ... concerns whether Anthera and certain of its officers and/or directors ... Act of 1934. ...
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), ... report to their offering. ... The global active pharmaceutical ingredients market is expected to ... 2016, growing at a CAGR of 6.3% from 2016 to 2021. ...
Breaking Medicine Technology: